Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
In recent years, there have been numerous new medications evaluated for treatment of ocular inflammation. As with all new medications, there has been the issue of cost. This month, Melissa Toyos, MD, FACS, discusses a controversial new “old” anti-inflammatory medication that, while it may have tremendous potential to treat many conditions, may be cost prohibitive. We hope you
Uncategorized